The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transfer of Convertible Loan Notes

12 Oct 2016 07:00

RNS Number : 2789M
Byotrol PLC
12 October 2016
 

 

12 October 2016

 

Byotrol plc

 

("Byotrol" or the "Company")

 

Transfer of Convertible Loan Notes within Company Directorship

 

Further to the announcements of 09 September 2016 and 30 September 2016 regarding the amendment to the terms of the Company's Convertible Loan Notes (the "Loan Notes"), Byotrol has been informed of a transfer of ownership of a portion of those Loan Notes between the Company's senior management team, as further detailed in the table below

Name

Loan Note ownership pre transfer

Loan Notes ownership post transfer

Number of Ordinary Shares to be issued if Loan Notes are converted

Existing number of Ordinary Shares held

Percentage holding following conversion of the Loan Notes

David Traynor

 £50,000

 £0

 0

 4,850,514

 1.81%

Till Medinger

 £30,000

 £40,000

 1,070,932

 1,164,367

 0.83%

Trevor Francis

 £0

 £40,000

 1,070,932

 1,110,359

 0.81%

Nicholas Martel

 £50,000

 £50,000*

 1,338,665

 18,627,362**

 7.45%

 

* non-beneficial holding

** includes a non-beneficial interest in 16,527,362 Ordinary Shares

 

Based on the issue size of £380,000, the Loan Notes would, if converted, represent approximately 10,173,854 Ordinary Shares, amounting to 3.79 per cent. of the current issued share capital of the Company.

Enquiries:

Byotrol plc

01925 742 000

David Traynor - Chief Executive

 

 

finnCap Ltd

 

020 7220 0500

(Nominated Adviser & Broker)

Geoff Nash/Carl Holmes/James Thompson - Corporate Finance

Mia Gardner - Corporate Broking

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist in developing, formulating and commercialising cutting-edge antimicrobial technologies.Our patented suite of technologies delivers powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens

 

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives.

For more information, please go to www.byotrol.co.uk

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Traynor

2.

Reason for the Notification

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

N/A

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Convertible Loan Note

Identification code

GB00B0999995

b)

Nature of the transaction

Sale of Convertible Loan Note

c)

Price(s) and volume(s)

£50,000 Convertible Loan Notes sold at value

d)

Aggregated information:

· Aggregated volume

· Price

£50,000 Convertible Loan Notes sold at value

e)

Date of the transaction

11 October 2016

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

5.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Till Medinger

6.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial

7.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

N/A

8.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Convertible Loan Note

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Convertible Loan Note

c)

Price(s) and volume(s)

£10,000 Convertible Loan Note purchased at value

d)

Aggregated information:

· Aggregated volume

· Price

£10,000 Convertible Loan Note purchased at value

e)

Date of the transaction

11 October 2016

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

9.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Trevor Francis

10.

Reason for the Notification

a)

Position/status

Chief Technology Officer

b)

Initial notification/Amendment

Initial

11.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

N/A

12.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Convertible Loan Note

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Convertible Loan Note

c)

Price(s) and volume(s)

£40,000 Convertible Loan Note purchased at value

d)

Aggregated information:

· Aggregated volume

· Price

£40,000 Convertible Loan Note purchased at value

e)

Date of the transaction

11 October 2016

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHDFLFFQBFBFBQ
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.